Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Microsoft’s Xbox to Cut 3200 Jobs, Divest Studios in Overhaul | Bloomberg Intelligence
Posted
July 6, 2026
Views
1,277
Likes
5
Comments
2
Engagement
July 6, 2026
1,277
5
2
0.55%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Episode Timeline
Every episode in order around the one you’re watching — click any card and the page flips straight to it.
24:42Now PlayingWatch Paul and Scarlet LIVE every day on YouTube
Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu
- Brody Ford, Bloomberg Technology Reporter, discusses Microsoft Corp.'s Xbox plans to eliminate 3,200 jobs, or around 20% of its staff over the next year, as part of a massive reorganization to spur growth in the struggling gaming division. Xbox will divest four of its video-game development studios and is beginning the process to part ways with a fifth, with the goal of streamlining the business and reinvesting in bigger projects.
- Bailey Lipschultz, Bloomberg News Senior Equities Reporter, discusses SK Hynix kicking off the formal marketing process for its US listing, seeking to sell American depositary receipts representing about 17.79 million common shares. The company is looking to capitalize on surging investor demand for the high-flying memory-chip sector, with the offering of ADRs coming after the firm’s Seoul-traded stock rallied about 260% this year.
- Tim Craighead, Bloomberg Intelligence Global Chief Content Officer, discusses 10 companies to watch in Q3. Bloomberg Intelligence analysts have identified interesting companies from their roster of high-confidence Focus Ideas. Spanning sectors and regions, each scenario outlines a catalyst in the next few months that supports our case.
- Sam Fazeli, Bloomberg Intelligence Director of Research: Healthcare, Defence, Industrials & Autos, discusses Novartis AG agreeing to buy Myricx Bio for as much as $1.5 billion, adding an experimental cancer drug designed to deliver more potent treatments directly to tumors while limiting damage to healthy cells.
See omnystudio.com/listener () for privacy information.
Paul Sweeney and the Bloomberg News team cover the day's market action, with analysis from Bloomberg Intelligence analysts, Bloomberg Opinion writers and influential newsmakers.
Watch us LIVE on YouTube
Subscribe to Bloomberg Podcasts
Listen to more Bloomberg Intelligence
#News #Markets #Bloomberg #Podcast #Business #Finance
Follow Bloomberg Podcasts on Twitter
Visit our other YouTube channels:
Bloomberg Television
Bloomberg Originals
For coverage on news, markets and more
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
